Need an oil spill lawyer? We will fight for you!
› $150,000,000 verdict in personal injury case
A decrease in reported cases of breast cancer across the country linked to the decline of hormone replacement therapy (HRT) is more significant in affluent, urban areas, according to a study published in the journal BMC Medicine.
U.S. District Judge Bill Wilson Jr. has ordered scientific data collected by the Cancer Research Center since August 2005 as a follow up to a study on the effects of hormone replacement therapy (HRT) on postmenopausal women should be released to Wyeth Pharmaceuticals as it defends itself against numerous lawsuits over the safety of its HRT meds.
Researchers in Ottawa, Canada are hoping to ease women’s fear of hormone replacement drugs by creating and testing synthetic hormones to combat aggravating symptoms of menopause, according to Canada.com. The research follows an earlier grant from the Canadian Breast Cancer Foundation to explore the re-engineering of estrogen estradiol, which is one of the components of the popular hormone replacement therapy (HRT) Premarin. The new grant, funded by a $267,000 research grant from the Canadian Breast Cancer Foundation, seeks to evaluate those compounds of synthesized molecules on the liver, cardiac and other types of cells. The goal is that it must relieve menopausal symptoms while not promoting breast or uterine cancer.
Women who took Wyeth’s hormone replacement therapy (HRT) Prempro at least five years are at greater risk of dying from non-small cell lung cancer, according to a recent study presented at an American Society of Clinical Oncology meeting.
The Food and Drug Administration (FDA) is expected to issue a warming to doctors about an increased risk of the recurrence of breast cancer with patients taking both the breast cancer drug tamoxifen and select antidepressants, according to a study released last week at the American Society of Clinical Oncology’s annual meeting.
Women on hormone replacement therapy (HRT) who have no family history of breast cancer have the same risk of developing breast cancer as women with a family history who are on HRT, according to a University of Rochester Medical Center Study.
The more than 2 million baby-boomer women who are approaching menopause may find themselves in a precarious position when it comes to handling hot flashes and mood swings. Should they risk the threat of breast cancer from use of hormone replacement therapy, or simply suffer through the agonizing symptoms? According to Forbes, new and detailed research offers women the opportunity to make a more educated decision.
A new study published this week in the New England Journal of Medicine suggests a sudden decrease in breast cancer in several countries worldwide is likely linked to the 2002 Women’s Health Initiative (WHI) finding that hormone replacement therapy (HRT) after menopause can dramatically increase a woman’s risk of breast cancer and other serious health problems, the Wall Street Journal reports.
A federal study revealed that the pharmaceutical company Wyeth paid ghostwriters to write articles for medical journals that were favorable to the drug company’s hormone replacement therapy (HRT) Prempro, even after the drug was found to raise a woman’s risk for breast cancer, according to the New York Times.
Hormone replacement therapy (HRT) and its link to breast cancer and other serious conditions continue to make headlines. This week, U.S. News & World Report announced that women who take HRT and then get breast cancer are at lower risk of dying from their disease, according to a new study by the University of California-Irvine.
![[ Beasley Allen Law Firm Logo ]](http://www.hrt-legal.com/wp-content/themes/system-unity/images/logo.png){kind=logo}
